Year: 2021

EXCLUSIVE: Flagship Pioneering Company Kintai Therapeutics Focuses on Enteric Therapeutics

The vast majority of immune cells are found in the gut but historically, the gut has been viewed as a liability to drug development. The question of whether or not greater understanding of harnessing the gut could drive more promising drug development has led to the formation of a new company, Kintai Therapeutics.

View article: https://www.biospace.com/article/exclusive-flagship-ventures-company-kintai-therapeutics-focuses-on-enteric-therapeutics/

Industry veterans Paul Peter Tak and Eric Meldrum join Citryll’s Board

Paul Peter Tak, MD, PhD served as Professor of Medicine and Chair of the Department of Clinical Immunology and Rheumatology at the Academic Medical Centre/University of Amsterdam (AMC). At GlaxoSmithKline (GSK) he served as Senior Vice President, Chief Immunology Officer, and Global Development Leader, and oversaw the creation of a portfolio of new medicines for immune-mediated inflammatory diseases, cancer and infectious diseases. He has been CEO of Tempero Pharmaceuticals and Kintai Therapeutics, a Flagship Pioneering company, and served on the Board of multiple biotech companies.

View Article: https://apnews.com/press-release/Business%20Wire/110ab5d1a7874299b67d738c54518cec

CANDEL THERAPEUTICS APPOINTS PHARMA VETERAN AND IMMUNOLOGIST PAUL-PETER TAK, M.D., PH.D., AS CHIEF EXECUTIVE OFFICER; EXPANDS LEADERSHIP TEAM WITH CHIEF FINANCIAL OFFICER, CHIEF BUSINESS OFFICER AND CHIEF REGULATORY OFFICER APPOINTMENTS

– Advancing oncolytic viral immunotherapies that light up and destroy local tumors, while creating a durable and systemic immune response
– Phase 3 prostate cancer program enrolling patients, clinical data readouts from other ongoing clinical programs in 2021
– Company founder and former CEO Estuardo Aguilar-Cordova, M.D. inf., Ph.D., takes on role of chief scientific officer
– Nathan Caffo named chief business officer; John Canepa appointed as chief financial officer; Susan Stewart named chief regulatory officer

Pioneering Gut Science, Kintai Therapeutics Is Bringing a New Small Molecule Modality to Fruition

What if the gut, widely regarded as the body’s second brain, could offer a much more impactful means to effect broad systemic pharmacological actions of orally administered drugs based on the confluence of the enteric nervous system, immune system, and microbiome within it?

View Article: https://wxpress.wuxiapptec.com/pioneering-gut-science-kintai-therapeutics-is-bringing-a-new-small-molecule-modality-to-fruition/

GSK-Backed Sitryx Launches With Six Immunometabolism Eggs In Its Basket

GlaxoSmithKline, SV Health Investors and Sofinnova are among the backers of a new Oxford-based biotech which has raised $30m in series A financing and boasts a strong line-up of academic founders. CEO Neil Weir outlines Sitryx’s raison d’etre.

View Article: https://hbw.pharmaintelligence.informa.com/SC123958/GSK-Backed-Sitryx-Launches-With-Six-Immunometabolism-Eggs-In-Its-Basket

Going with Your Gut Instinct

I’ve been interested in this field since before the term “microbiome” was coined. In the 1990s, I conducted research at Leiden University Medical Center on the role of microorganisms in the pathogenesis of rheumatoid arthritis (RA). We were the first to take biopsies from the target tissues of inflamed joints of patients with RA and other forms of inflammatory joint disease, and analyze them using 16s PCR. We detected microbial DNA in different forms of arthritis and predicted that it would be derived from the gut.

Paul Peter Tak

© Paul Peter Tak.
All rights reserved.